SUPPLEMENTAL FIGURES

WT
under the control of a neuron-specific synapsin promoter were bilaterally delivered into the VMH (AP, -1.5 mm; ML, ±0.3 mm; DV, -5.8 mm) or in the ARC (AP, -1.5 mm; ML, ±0.15 mm; DV, -6.0 mm). For cannulation studies involving VMH WT and VMH ΔABHD6 mice, mice were first injected with the AAV vectors unilaterally in the left VMH (ML, -0.3 mm) using a neurosyringe as described above. A single guide cannula (26 gauge; Plastics One, Roanoke, VA, USA) was then lowered 2 mm above the right VMH (AP, -1.5 mm; ML, +0.3 mm; DV, -3.8 mm). The cannula was anchored to the skull surface with dental cement, immediately used for the second AAV vectors delivery using an internal cannula (extending 2 mm below the guide cannula) attached to a 1 μl Hamilton microsyringe via tubing, and then occluded with a dummy cannula. All surgeries were followed by a 10-day recovery period. Following sham handling, cannulated animals received unilateral VMH injections (in a volume of 500 nl) using an internal cannula as described (1.25 μg orlistat in 20% DMSO, 1 μg WWL70 in 20% DMSO or vehicle [20% DMSO]).
VMH 2-AG levels
Animals were anaesthetized and decapitated. The brain was quickly harvested and the VMH excised from fresh sagittal sections using anatomical landmarks. Isolated VMH were snap frozen in liquid N 2 and stored at -80°C until use. The whole procedure was performed in less than 2 minutes and brain and sections were kept on ice during that period. Samples were homogenized at 5500 rpm for 25s at 4°C using a Precellys 3D-homogenizer (Bertin Technologies, Villeurbanne, France) in buffer (200 mM sucrose, 50 mM Tris-HCl, 5 mM MgCI 2 , 2.5 mM EDTA, pH 7.4) containing 66% toluene (v/v) spiked with10 ng deuterium labeled 2-AG internal standard (2AG-d5). Two successive liquid-liquid extractions were performed at 4°C with 2 and 1 volumes of toluene respectively (Felder et al., 1996) . Phase separation was done by centrifugation at 3500g for 15 min at 4°C. The two upper toluene phases were pooled in a silanized glass tube and dried under N 2 . Dried organic extracts were reconstituted in 40 µl of 2 mM ammonium acetate in methanol and 2 mM ammonium acetate in water (4:1, v/v), vortex for 15s and centrifuged at 13,000×g for 5 min. 30µl of clear supernatant was then transferred to a silanized insert and place in a vial for analysis.
Quantitative analysis of 2-AG in VMH samples was performed by HPLC tandem MS/MS; adapted from previously described methodology (Zoerner et al., 2012) , on an Agilent 1200 SL system (HPLC) coupled to a triple quadrupole mass spectrometer (4000Q TRAP MS/MS, SCIEX). Briefly, samples were resolved on a Zorbax Eclipse Plus-C18 (2.1 mm x 100 mm, 1.8 µm particle size) column (Agilent Technologies) at 0.35 mL/min with column temperature set at 60°C. The mobile phase consisted of solvent A (2 mM ammonium acetate in water) and solvent B (2 mM ammonium acetate in methanol). The following gradient was applied: 0.0 to 0.5 min 80% B, 0.5 to 6 min to 87% B, 6.0 to 7.2 to 100% B, and 7.2 to 9 min 80% B. The MS was operated in positive electrospray ionization mode using a turbo ion spray source. 2-AG/1-AG and 2-AG-d5 were measured on multiple reaction monitoring mode (MRM) . Compound optimization of 2-AG/1-AG was based on the fragmentation of the precursor ion 379.3m/z that yield a prominent product ion at 287.5m/z. The 2-AG-d5 internal standard optimization reported the 384.5m/z precursor ion to yield the predominant 287.5 m/z fragment. Quantification was performed by integrating peak areas from the selected transitions using Multiquant software (version 2.0.2; SCIEX). 2-AG levels were determined using a specific standard curve. Due to the rapid isomerization of 2-AG into 1-AG in biological matrix (Zoerner et al., 2012) , 2-AG was quantified as the sum of 2-AG and 1-AG.
